NCT06417814: An ongoing trial by AstraZeneca
This trial is ongoing. It must report results 1 year, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06417814 |
|---|---|
| Title | A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 4, 2024 |
| Completion date | Sept. 30, 2026 |
| Required reporting date | Sept. 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |